Table 2 10 largest global deals with generic targets from 1995 to 2016 a,b,c
From: Merger mania: mergers and acquisitions in the generic drug sector from 1995 to 2016
Target | Acquirer | Announced value (in billions) | Announced date | Completion date |
|---|---|---|---|---|
Allergan’s generic drug business | Teva Pharmaceutical Industries Ltd | 39.56 | 27 July 2015 | 2 August 2016 |
Hospira Inc | Pfizer Inc | 16.81 | 5 February 2015 | 3 September 2015 |
Nycomed A/S | Takeda Pharmaceutical Co Ltd | 13.73 | 19 May 2011 | 30 September 2011 |
Barr Pharmaceuticals Inc | Teva Pharmaceutical Industries Ltd | 8.83 | 18 July 2008 | 23 December 2008 |
Par Pharmaceutical Holdings Inc | Endo International PLC | 8.09 | 18 May 2015 | 28 September 2015 |
IVAX Corp | Teva Pharmaceutical Industries Ltd | 7.58 | 25 July 2005 | 26 January 2006 |
Merck Generics | Mylan NV | 6.62 | 12 May 2007 | 2 October 2007 |
Hexal AG | Novartis AG | 5.69 | 21 February 2005 | 7 June 2005 |
Actavis Group HF | Allergan plc | 5.61 | 25 April 2012 | 31 October 2012 |
Developed markets branded generics pharmaceuticals | Mylan NV | 5.61 | 14 July 2014 | 27 February 2015 |